Vivodyne is a biotechnology company developing highly scalable drug testing on lab-grown 3D human tissues to accelerate therapeutic discovery. Its platform technology, Pipeline V, creates a preclinical drug development pipeline from start to finish using lab-grown human organs. The system can test on over 10,000 independent human tissues simultaneously, drawing on more than 20 organ models spanning major human organ systems. According to the company, it produces more human data than all clinical trials in the United States combined.
The company works across biopharma, pharmaceutical research, and therapeutic development, applying expertise in 3D human tissue engineering, robotics, and AI models. Vivodyne aims to replace pharmaceutical animal testing with a more ethical, scalable, and human-relevant alternative. The company was named number one in Fast Company's World's Most Innovative 'Small but Mighty' Companies for 2022.
Vivodyne has raised $82 million in total funding, including a $40 million Series A round. Its stated mission is to accelerate the discovery of cures to human diseases.
